Welcome to Tokai Pharmaceuticals
Tokai Pharmaceuticals is a privately held U.S. biopharmaceutical company based in Cambridge, MA, focused on developing new treatments for prostate cancer.
The company's lead drug candidate, galeterone (TOK-001), is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined in one drug. Galeterone is currently in clinical development and is being studied in patients with castration resistant prostate cancer (CRPC).
The company was founded by Apple Tree Partners. In September 2011, Tokai announced that the company closed $23 million in additional funding from both existing investors, Apple Tree Partners and Novartis Venture Fund (NVF). Read more about Tokai’s financing.
